Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

Ardizzoni, Andrea; Tiseo, Marcello; Boni, Luca; Maïo, Massimo Di; Buffoni, L; Belvedere, Ornella; Grossi, Francesco; D’Alessandro, Vito; Marinis, Filippo de; Barbera, Santi; Caroti, C.; Favaretto, Adolfo; Cortinovis, Diego; Morrica, Brunello; Tixi, Lucia; Ceschia, Tino; Parisi, Salvatore; Ricardi, Umberto; Loreggian, L.; Navarria, Pierina; Huber, Rudolf M.; Belani, Chandra P.; Bruswig, Paal Fr; Scagliotti, Giorgio Vittorio; Scolaro, Tindaro

doi:10.1016/j.lungcan.2016.07.026

Cited by 3 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Non-small cell lung cancer (NSCLC), which includes squamous cell carcinoma and adenocarcinoma, is a highly metastatic subset of lung cancer ( 2 - 4 ). At present, typical treatments for NSCLC include surgery, radiotherapy and chemotherapy; however, despite advances in these techniques, the median survival period of patients with late-stage and metastatic NSCLC remains unsatisfactory ( 5 - 7 ). As such, developing novel effective treatments for NSCLC is of utmost importance.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

Jiang¹,

Yu²,

Chu³

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

MicroRNAs (miRNAs or miRs) have recently emerged as key regulators of various types of cancer, including non-small cell lung cancer (NSCLC). The disrupted expression of miRNAs is associated with tumorigenesis and metastasis; however, the underlying mechanisms remain unclear. In this study, we demonstrate that miR-98-5p is downregulated in NSCLC and that miR-98-5p deficiency is associated with an advanced clinical stage and metastasis. A dual-luciferase reporter assay was performed to confirm that transforming growth factor beta receptor 1 (TGFBR1), a key stimulator of tumor proliferation and metastasis, was a direct target of miR-98-5p. miR-98-5p overexpression resulted in the downregulation of TGFBR1 and the suppression of the viability, proliferation, migration and invasion of A549 and H1299 cells. Furthermore, miR-98-5p was demonstrated to be an efficient suppressor of tumor growth in an A549 subcutaneous xenograft tumor mouse model. Finally, miR-98-5p overexpression exerted a significant anti-metastatic effect in a mouse model of pulmonary metastasis. On the whole, the results of the present study suggest that miR-98-5p/TGFBR1 may serve as promising targets for NSCLC therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

Jiang¹,

Yu²,

Chu³

et al. 2018

Int J Oncol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

“…Ardizzoni found that the addition of single agent taxane given concurrently to radiotherapy failed to significantly improve survival after platinum-based induction in locally advanced NSCLC. 36 In addition, a number of previous studies have discussed the role of the neutrophil-to-lymphocyte ratio (NLR) in the prognostic assessment of NSCLC and have demonstrated that an increase in NLR over the course of radiotherapy had a negative impact on survival. 37 Some studies have shown that NLR is associated with inferior outcomes in localized NSCLC treated with SBRT.…”

Section: Discussionmentioning

confidence: 99%

Combined Radiomics–Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer

Chen

Wang

Hou

et al. 2022

Technol Cancer Res Treat

View full text Add to dashboard Cite

Purpose: Radiotherapy is a promising treatment option for lung cancer, but patients’ responses vary. The purpose of the study was to investigate the potential of radiomics and clinical signature for predicting the radiotherapy sensitivity and overall survival of inoperable stage III and IV non-small-cell lung cancer (NSCLC) patients. Materials: This retrospective study collected 104 inoperable stage III and IV NSCLC patients at the Yunnan Cancer Hospital from October 2016 to September 2020. They were divided into radiation-sensitive and non-sensitive groups. We used analysis of variance (ANOVA) to select features and support vector machine (SVM) to build the radiomic model. Furthermore, the logistic regression method was used to screen out clinically relevant predictive factors and construct the combined model of radiomics–clinical features. Finally, survival was estimated using the Kaplan–Meier method. Results: There were 40 patients in the radiation-sensitive group and 64 in the non-sensitive group. These patients were divided into training set (73 cases) and testing set (31 cases) according to the ratio of 7:3. Nine radiomics features and one clinical feature were significantly associated with radiotherapy sensitivity. Both the radiomics model and combined model have good predictive performance (the areas under the curve (AUC) values of the testing set were 0.864 (95% confidence interval [CI]: 0.683-0.996) and 0.868 (95% CI: 0.689-1.000), respectively). Only platelet level status was associated with overall survival. Conclusion: The combined model constructed based on radiomics and clinical features can effectively identify the radiation-sensitive population and provide valuable clinical information. Patients with higher platelet levels may have a poor prognosis.

show abstract

Radiation Therapy in Non-small-Cell Lung Cancer

Gückenberger¹,

Pöttgen²,

Stuschke³

2019

Radiation Oncology

View full text Add to dashboard Cite

Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC

Cited by 3 publications

References 28 publications

MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

MicroRNA-98-5p inhibits proliferation and metastasis in non-small cell lung cancer by targeting TGFBR1

Combined Radiomics–Clinical Model to Predict Radiotherapy Response in Inoperable Stage III and IV Non-Small-Cell Lung Cancer

Radiation Therapy in Non-small-Cell Lung Cancer

Contact Info

Product

Resources

About